Follicular Lymphoma

The most common indolent NHL — t(14;18)/BCL2 translocation, watch-and-wait for asymptomatic low-burden disease, and rituximab-based chemoimmunotherapy for symptomatic disease

Key Points

• Follicular lymphoma (FL) is the most common indolent B-cell NHL, accounting for ~20% of all NHL; the hallmark translocation t(14;18)(q32;q21) juxtaposes BCL2 to the IGH enhancer, driving constitutive BCL-2 anti-apoptotic signaling.
• FL follows an indolent, relapsing-remitting course with a median OS now exceeding 18–20 years in the rituximab era; early-stage disease is potentially curable with radiation, but most patients present at advanced stage.
• Watch-and-wait (active surveillance) is appropriate for asymptomatic, low-tumor-burden FL (defined by absence of GELF criteria); randomized trials show no OS detriment from deferring therapy.
• Symptomatic or high-tumor-burden FL is treated with bendamustine + obinutuzumab (or rituximab), or R-CHOP, followed by 2-year anti-CD20 maintenance; BR + obinutuzumab demonstrated superior PFS over BR + rituximab (GALLIUM trial).
• EZH2 mutations (present in ~25% of FL, predominantly GCB subtype) predict response to tazemetostat; tazemetostat is FDA-approved for relapsed/refractory EZH2-mutated and EZH2 wild-type FL.
• Histologic transformation to DLBCL (rate ~2–3%/year, cumulative ~30% at 10 years) is the most feared complication of FL, converting an indolent disease into an aggressive one requiring DLBCL-directed chemoimmunotherapy.

Epidemiology, Pathogenesis, and Classification

Follicular lymphoma accounts for approximately 14,000–16,000 new cases annually in the United States and is the second most common B-cell lymphoma after DLBCL. It predominantly affects middle-aged to older adults (median age ~60) with a slight female predominance. FL is rare before age 30. **Molecular Pathogenesis:** The t(14;18)(q32;q21) translocation — present in ~85–90% of FL — places the BCL2 proto-oncogene on chromosome 18q21 under control of the IGH enhancer on 14q32, leading to constitutive BCL-2 overexpression. BCL-2 inhibits apoptosis, prolonging the survival of germinal center B…

Clinical Presentation and Diagnosis

FL typically presents with painless, slowly progressive lymphadenopathy that has often waxed and waned for months to years before diagnosis. Many patients are asymptomatic at diagnosis, discovered incidentally on imaging or during workup for other conditions. **Common features:** - Generalized peripheral lymphadenopathy (cervical, axillary, inguinal, retroperitoneal) — often multiple sites simultaneously - Splenomegaly (~30–40%) - Bone marrow involvement (~70%): Characteristic paratrabecular aggregates of small cleaved cells; may cause mild cytopenias - Peripheral blood involvement (leukemic…

Staging and Risk Stratification

FL is staged using the Lugano Classification. The majority of patients (~85%) present at stage III–IV, yet median OS in the rituximab era exceeds 18–20 years — underscoring the importance of avoiding overtreatment. **Follicular Lymphoma International Prognostic Index (FLIPI):** Incorporates 5 adverse factors (1 point each): Age >60, stage III–IV, Hgb ULN, >4 nodal sites involved: - Low risk (0–1): 10-year OS ~71% - Intermediate risk (2): 10-year OS ~51% - High risk (≥3): 10-year OS ~36% **FLIPI-2:** Revised index using beta-2 microglobulin, longest lymph node diameter >6 cm, bone marrow…

Treatment

**Stage I–II FL (limited disease, ~15% of patients):** Involved-site radiation therapy (ISRT) 24–30 Gy: Associated with 10-year PFS of ~50% and possibly curative in a proportion. Watch-and-wait is also reasonable for truly asymptomatic stage II patients who decline RT or have bulky disease unsuitable for RT. **Advanced-Stage, Low Tumor Burden (no GELF criteria — majority):** Watch-and-wait (active surveillance): Three randomized trials (Ardeshna, Solal-Céligny) demonstrate no OS benefit from early treatment vs. observation. Median time to first treatment is 2–3 years; many patients are never…

Histologic Transformation and Long-term Considerations

Histologic transformation (HT) to DLBCL is the most clinically significant complication of FL, converting an indolent disease into an aggressive, often rapidly fatal one if untreated. HT rate is ~2–3%/year, with a cumulative risk of ~25–30% at 10 years; the risk may be slightly lower in patients treated with rituximab-based regimens vs. older chemotherapy regimens. **Risk factors for transformation:** High FLIPI score, bone marrow involvement, high Ki-67 at initial diagnosis, early progression on first-line therapy (POD24 — progression within 24 months of first chemoimmunotherapy), and…